Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026)

Amarin Corp Plcuk (AMRN) posted quarterly Non-Current Assets of $19.8 million for Q1 2026, down 76.08% YoY from $82.6 million in Q1 2025, and down 5.4% sequentially from $20.9 million in Q4 2025.

Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026) Analysis & Trends

Amarin Corp Plcuk has disclosed Non-Current Assets across 17 years of filings, most recently posting $19.8 million for Q1 2026.

  • In Q1 2026, Non-Current Assets fell 76.08% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $135.5 million (down 63.49% YoY), while the FY2025 annual figure was $20.9 million, down 76.77% from the prior year.
  • Non-Current Assets eased to $19.8 million in Q1 2026, from $20.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for AMRN reached as high as $254.1 million in Q2 2022 and fell as low as $19.8 million in Q1 2026.
  • The 5-year median for Non-Current Assets is $102.1 million (2024), against an average of $120.1 million.
  • Annual changes were most pronounced in 2022 — Non-Current Assets surged 418.74% — and 2025, when it tumbled 76.77%.
  • A 5-year view of Non-Current Assets shows it stood at $197.1 million in 2022, then slumped by 45.86% to $106.7 million in 2023, then decreased by 15.7% to $90.0 million in 2024, then plunged by 76.77% to $20.9 million in 2025, then decreased by 5.4% to $19.8 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $19.8 million, $20.9 million, and $31.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 61.74 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 141.72 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 102.93 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 84.40 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 125.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 61.03 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 37.64 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 165.18 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Amarin Corp Plcuk 5.17 Bn 5.00 Bn 17.77 Mn 19.76 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 19.76 Mn
Dec 31, 2025 20.89 Mn
Sep 30, 2025 31.51 Mn
Jun 30, 2025 63.33 Mn
Mar 31, 2025 82.64 Mn
Dec 31, 2024 89.95 Mn
Sep 30, 2024 100.40 Mn
Jun 30, 2024 98.10 Mn
Mar 31, 2024 102.11 Mn
Dec 31, 2023 106.70 Mn
Sep 30, 2023 121.52 Mn
Jun 30, 2023 153.52 Mn
Mar 31, 2023 176.39 Mn
Dec 31, 2022 197.08 Mn
Sep 30, 2022 221.78 Mn
Jun 30, 2022 254.14 Mn
Mar 31, 2022 201.09 Mn
Dec 31, 2021 189.34 Mn
Sep 30, 2021 72.77 Mn
Jun 30, 2021 48.99 Mn